Archived explainer. For the current picture see today's PCVX page.
VAXCYTE INC (PCVX) is down -9.65% in the latest session. Our newswire has captured 22 stories on PCVX across 10 sources in the last 36 hours, with AI sentiment reading mixed (avg 49/100).
Vaxcyte Inc. (PCVX) fell 9.65% to $66.70 on October 6, 2026, amid a broad sell-off in biotech stocks and a sharp drop in the company’s shares following news of a new public offering. The stock’s decline coincided with broader market volatility and investor reaction to the company’s capital-raising announcement.
Vaxcyte announced the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock, pre-funded warrants, and convertible senior notes. The move, which was disclosed in a Globe NewsWire release, triggered immediate investor concern over potential dilution and signaled the company’s need for additional capital. The stock fell further as biotech stocks broadly declined, with Vaxcyte and Moderna among the hardest hit. The Fly reported a drop of -11.3% for the stock, and BofA raised its price target to $146 from $130, reflecting optimism about the company’s VAX-31 vaccine trial data. However, the market reaction was bearish, with the stock falling into a down trend despite recent positive developments in its clinical pipeline.
Over the past eight sessions, PCVX had risen 18.6% from $56.24 to $66.70, but the recent drop pushed it closer to its 52-week low of $39.87. The stock traded at a market cap of $8.4 billion, with a beta of 1.22, indicating higher volatility than the broader market. Unusual options activity included four notable prints, with call premiums totaling $341,000 and put premiums at $226,000. The largest single options trade was $271,000. Additionally, the stock printed 18 fresh 52-week lows on October 6. Recent insider transactions showed 7 sells totaling $3.1 million in the last 90 days, with the most recent filing on October 2.
Vaxcyte has no scheduled earnings date in the near term, but coverage breadth remains a key factor to monitor. With 22 stories from 10 sources in the last 36 hours, investor sentiment and analyst commentary could shift quickly based on further developments in the company’s pipeline or market conditions.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
SAN CARLOS, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of concurrent underwritten public offerings of 7,412,500 shares of common stock,...
Vaxcyte stays a Strong Buy after VAX-31 phase 3 OPUS-1 success; broader pneumococcal coverage and 2027 catalysts are ahead. Click for more on PCVX.
Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses.
BofA raises Vaxcyte stock price target to $146 on OPUS-1 data
Why is Vaxcyte stock sliding today?
More on PCVX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier PCVX move explainers: 2026-10-07 · 2026-10-06 · 2026-10-05